ZHONG Xuemei,CHEN Min,LING Yayun,et al.Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients[J].ZHONGGUO YAOFANG,2025,36(06):732-736.
ZHONG Xuemei,CHEN Min,LING Yayun,et al.Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients[J].ZHONGGUO YAOFANG,2025,36(06):732-736. DOI: 10.6039/j.issn.1001-0408.2025.06.16.
Clinical observation of metformin in the treatment of diabetes mellitus type 2 complicated with sarcopenia in elderly patients
To investigate the efficacy and safety of metformin in the treatment of diabetes mellitus type 2 (T2DM) complicated with sarcopenia in elderly patients.
METHODS
2
From January 2022 to January 2024, clinical data from eligible patients with T2DM complicated with sarcopenia treated at the First Affiliated Hospital of Chongqing Medical and Pharmaceutical College were collected. Patients were randomly assigned into control group (70 cases) and observation group (70 cases) using a random number table. Both groups received routine interventions; control group additionally received subcutaneous injections of Insulin glargine injection before bedtime and Human insulin injection 30 minutes before breakfast, lunch and dinner every day. In addition to the same treatments as the control group, the observation group was administered 0.5 g of Metformin hydrochloride sustained-release tablets orally once daily. Both groups were treated continuously for 24 weeks. Comparisons were made between the two groups in terms of glucose metabolism indexes [fasting blood glucose (FBG), 2 h postprandial blood glucose (2 hBG), and glycosylated hemoglobin (HbA1c)], homeostasis model assessment of insulin resistance (HOMA-IR), appendicular skeletal mass muscle index (ASMI), grip strength, walking speed, lipid metabolism indexes [serum total triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)], serological markers [high-sensitivity C reactive protein (hs-CRP), interleukin-6 (IL-6), and ferritin levels] and quality of life. The occurrence of ADR was recorded in both groups.
RESULTS
2
65 patients in the control group and 63 patients in the observation group completed this study, respectively. After treatment, the levels of FBG, 2 hBG, HbA1c, HOMA-IR, TG and TC in both groups, and the levels of hs-CRP, IL-6 and ferritin in observation group were all significantly reduced compared to those before treatment (
P
<0.05), and the HOMA-IR in observation group was significantly lower than control group (
P
<0.05); additionally, the grip strength, walking speed, and scores for daily living and activity abilities of observation group were increased than those before treatment and the control group (
P
<0.05). The incidence of adverse drug reactions in both groups was 2.86%.
CONCLUSIONS
2
Metformin can reduce inflammatory factors and ferritin levels, promote the recovery of muscle mass and strength, improve insulin resistance, and quality of life in elderly patients with T2DM complicated with sarcopenia, and does not increase the occurrence of adverse drug reactions.
关键词
Keywords
references
CHO M R , LEE S , SONG S K . A review of sarcopenia pathophysiology,diagnosis,treatment and future direction [J ] . J Korean Med Sci , 2022 , 37 ( 18 ): e146 .
XIE W Q , HE M , YU D J , et al . Mouse models of sarco-penia:classification and evaluation [J ] . J Cachexia Sarcopenia Muscle , 2021 , 12 ( 3 ): 538 - 554 .
CUI H , WANG C H , WU J Q , et al . Chinese expert consensus on prevention and intervention for elderly with sarcopenia:2023 [J ] . Chin J Geriatr , 2023 , 42 ( 2 ): 144 - 153 .
ZHONG W , XIE C G , GAO H , et al . Recent progress of relationship between diabetes and sarcopenia [J ] . Chin J Diabetes , 2017 , 25 ( 7 ): 662 - 665 .
ZHAO Y , MENG D Q , XU Q , et al . Correlation between sarcopenia and senile type 2 diabetes mellitus with osteoporosis based on CT [J ] . Chin J Gerontol , 2023 , 43 ( 5 ): 1046 - 1050 .
QAISAR R , KARIM A , MUHAMMAD T , et al . Metformin improves sarcopenia-related quality of life in geriatric adults:a randomized controlled trial [J ] . Arch Med Res , 2024 , 55 ( 4 ): 102998 .
TEZZE C , AMENDOLAGINE F I , NOGARA L , et al . A combination of metformin and galantamine exhibits synergistic benefits in the treatment of sarcopenia [J ] . JCI Insight , 2023 , 8 ( 15 ): e168787 .
Chinese Diabetes Society of the Chinese Medical Association . Reaction to guideline for the prevention and treatment of type 2 diabetes mellitus in China:2020 edition [J ] . Chin J Diabetes Mellit , 2021 , 13 ( 4 ): 315 - 409 .
CHEN L K , LIU L K , WOO J , et al . Sarcopenia in Asia:consensus report of the Asian working group for sarco-penia [J ] . J Am Med Dir Assoc , 2014 , 15 ( 2 ): 95 - 101 .
LIM T O , MORAD Z . Reliability,validity and discriminatory ability of Spitzer’s QL-index in dialysis patients [J ] . Med J Malaysia , 1998 , 53 ( 4 ): 392 - 400 .
Expert Group for Updating Chinese Expert Consensus on Metformin in Clinical Practice . Chinese expert consensus on metformin in clinical practice:2023 update [J ] . Chin J Intern Med , 2023 , 62 ( 6 ): 619 - 630 .
YANG J P , WANG D Y , WEI W , et al . Time in range of glucose and sarcopenia in elderly patients with type 2 diabetes [J ] . Chin J Endocrinol Metab , 2022 , 38 ( 3 ): 179 - 185 .
SALOM VENDRELL C , GARCÍA TERCERO E , MORO HERNÁNDEZ J B , et al . Sarcopenia as a little-recognized comorbidity of type Ⅱ diabetes mellitus:a review of the diagnosis and treatment [J ] . Nutrients , 2023 , 15 ( 19 ): 4149 .
MESINOVIC J , FYFE J J , TALEVSKI J , et al . Type 2 diabetes mellitus and sarcopenia as comorbid chronic disea-ses in older adults:established and emerging treatments and therapies [J ] . Diabetes Metab J , 2023 , 47 ( 6 ): 719 - 742 .
HUANG A L , BU Z H , XUE M T , et al . Peripheral inflammatory markers in the patients with sarcopenia:a meta-analysis [J ] . Chin J Osteoporos , 2021 , 27 ( 7 ): 969 - 975 .
GELLHAUS B , BÖKER K O , SCHILLING A F , et al . Therapeutic consequences of targeting the IGF-1/PI3K/Akt/FOXO3 axis in sarcopenia:a narrative review [J ] . Cells , 2023 , 12 ( 24 ): 2787 .
WU M J , CHEN C , SHI B M . Change of serum ferritin in postmenopausal women with type 2 diabetes and sarcopenia [J ] . Chin J Osteoporos Bone Miner Res , 2020 , 13 ( 3 ): 222 - 228 .
PYRGIOTI E E , KARAKOUSIS N D , GEORGAKOPOULOS P N , et al . Metformin in type 2 diabetes:evidence for its beneficial effects on frailty and sarcopenia [J ] . Curr Diabetes Rev , 2024 , 20 ( 3 ): e270723219177 .